Both the firms have not disclosed the details of the agreement, under which AOP Orphan has agreed to specific annual commercial goals for AGGRASTAT.
The deal will see AOP Orphan responsible for the commercialization of AGGRASTAT in the AOP Orphan countries including Austria, Hungary, Switzerland, and other Eastern European states.
Cardiome chief commercial officer Karim Lalji said the company is happy to expand its relationship with AOP Orphan to include AGGRASTAT in addition to BRINAVESS.
"AGGRASTAT is an excellent fit with AOP’s established portfolio of cardiovascular products," Lalji said.
"We are looking forward to working with AOP to sell AGGRASTAT and to implement Cardiome’s commercialization strategy for this product."
AOP Orphan CEO Rudolf Widmann said the company is happy to partner and work with Cardiome to commercialize AGGRASTAT, the second Cardiome product in its cardiovascular portfolio.
"We are looking forward to selling AGGRASTAT to our existing customer base and to developing new customer relationships which will be key to the future growth of our cardiovascular franchise," Widmann said.